You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

EIGHT, the global educational initiative on Hemophilia A and its treatment

Experts from all over the world attended the EIGHT 2018 Conference in Budapest, Hungary on 12-13 October

read more 

EVENTS

Kedrion Biopharma participates in the Mother and Child Conference in Moscow

A 50 years of Anti-D dedicated programme presented at the main Russian congress of Gynecology and Obstetrics

read more 

EVENTS

Kedrion Joins Annual PNS Conference on Neurology

The company took part in the event with a booth and a delegation of 40 int’l guests

read more 

  1. EVENTS - 07-12-2015

    Hemophilia A. SIPPET study selected by the American Society of Hematology

    Presented at the ASH Congress in Orlando, it was chosen from amongst approximately three thousand studies

    read more 

  2. EVENTS - 09-11-2015

    Kedrion among the key players of Farmindustria's roadshow in Siena

    The Lucca-based company presented as one of the innovative pharmaceutical companies in Tuscany

    read more 

  3. CORPORATE - 12-10-2015

    Kedrion supports Fondazione Paracelso's activities in Afghanistan

    Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries

    read more 

  4. CORPORATE - 29-09-2015

    Kedrion Notes 2019 Tender Offer results

    Kedrion has accepted for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000

    read more 

Pages

For more information please contact: pressoffice@kedrion.com